AUS
NZ
UK
CA
USA
IND
Recce Pharmaceuticals Ltd (ASX:RCE) has announced the termination of 130,001 unlisted employee Options after the failure to satisfy the requisite conditions, as detailed in a company update filed on 2 July 2026. These options, part of the RCEAO series with an exercise price of $0.56 and expiring on 7 November 2029, were forfeited or lapsed on various dates between 26 April 2026 and 5 June 2026. The company did not pay any consideration related to this cessation. This update offers investors enhanced clarity on Recce Pharmaceuticals' current unquoted Equity securities following the reduction in its unlisted options pool.
Key Points
- Company: Recce Pharmaceuticals Ltd (ASX:RCE)
- 130,001 unquoted employee options (RCEAO series, exercise price $0.56, expiry 7 November 2029) have been terminated
- Options lapsed due to conditions not being met or becoming impossible to satisfy
- Cessation occurred on multiple dates from 26 April 2026 to 5 June 2026, with 5 June 2026 as the final date
- No consideration was paid by Recce Pharmaceuticals for the termination
- Total quoted ordinary shares remain at 299,318,821 after the change
- Investors should monitor any further updates to the company's unquoted securities or future employee incentive schemes
Impact of the 130,001 RCEAO Options Lapse on Recce Pharmaceuticals' Capital Structure
The termination of 130,001 options in the RCEAO series reduces Recce Pharmaceuticals' unquoted equity securities pool. These unlisted options, not traded on the ASX, were part of employee incentive programs. Their lapse does not affect the number of ordinary fully paid shares, which remains at 299,318,821.
Post-termination, the RCEAO class—options expiring 7 November 2029 at $0.56 exercise price—now totals 2,493,332 securities outstanding, down from the prior amount before the cancellation. The company confirmed that no payment was made for the forfeiture or lapse, indicating no direct impact on the company's Balance Sheet from this event.
Reasons Behind the Forfeiture of Unlisted Employee Options
The company update explains that the options ceased because attached conditions were either unmet or became impossible to fulfill. This is a standard feature of employee option plans, where performance targets, service requirements, or other vesting criteria must be achieved for options to convert into shares. If conditions remain unsatisfied, options lapse and revert to the company without compensation.
Recce Pharmaceuticals noted the final cessation date recorded in the Appendix 3H notification was 5 June 2026, with forfeitures occurring on various dates from 26 April 2026 through to that final date. This staggered pattern aligns with individual employee option holders’ conditions lapsing at different times rather than a single bulk cancellation.
Timeline of Option Cessations Between April and June 2026
The update clarifies that the 130,001 option terminations occurred progressively between 26 April 2026 and 5 June 2026. The Appendix 3H form, used for ASX market notifications of ceased securities, lists 5 June 2026 as the final cessation date for reporting purposes.
This phased cessation likely reflects multiple employees departing or failing to meet vesting milestones at different points during this six-week span. The company did not provide further details on individual lapse circumstances, consistent with typical disclosure practices for unlisted employee incentives.
Recce Pharmaceuticals' Remaining Unquoted Options and Warrants Post-Termination
Following the lapse, Recce Pharmaceuticals’ unquoted equity register includes 435,000 options under the RCEAW series expiring 11 February 2027 at a $1.56 exercise price; 2,493,332 options under the RCEAO series expiring 7 November 2029 at $0.56; 1,125,000 options under the RCEAU series with various expiries and prices; and 11,500,000 options under the RCEAP series expiring 14 November 2029 at $0.80.
The company also holds 4,634,304 outstanding warrants classified as RCEAQ. Collectively, all unquoted options and warrants total approximately 20,187,636 securities. The largest unquoted option class remains the RCEAP series with 11,500,000 options, representing a considerable potential dilution source if exercised, subject to conditions and in-the-money status.
Quoted Share Capital Remains at 299,318,821 Ordinary Shares
It is important for investors to note that the termination of unquoted options does not impact the number of ordinary fully paid shares quoted on the ASX. Recce Pharmaceuticals’ quoted capital remains steady at 299,318,821 ordinary shares (ASX Code: RCE). Since lapsed options are not exercised, no dilution occurs from this event.
In fact, the lapse of these employee options slightly reduces potential future dilution that would have arisen if the 130,001 options had been exercised at $0.56 each. The company did not disclose potential proceeds had these options been exercised prior to lapsing.
No Payment Made by Recce Pharmaceuticals for Option Termination
The Appendix 3H notification confirms that Recce Pharmaceuticals did not pay any consideration for the cessation of these securities. The company neither repurchased nor compensated option holders for the forfeiture or lapse of the 130,001 RCEAO options, which simply expired according to the original grant terms.
This is standard in employee incentive plans, where unvested or conditionally vested options are forfeited without compensation if conditions are unmet. The absence of payment means no direct financial outflow occurred, distinguishing this from share buybacks or negotiated option cancellations.
Comparison of Recce Pharmaceuticals' Option Classes After RCEAO Reduction
With the RCEAO series now reduced to 2,493,332 options, it is no longer the largest unquoted option class. The RCEAP series, with 11,500,000 options expiring 14 November 2029 at an exercise price of $0.80, is now the largest by volume. The RCEAW and RCEAU classes are smaller, at 435,000 and 1,125,000 options respectively.
Investors should note that the RCEAW series, expiring February 2027 with a $1.56 exercise price, carries the highest strike price among the option classes, meaning these options would only be profitable if the share price exceeds that level before expiry. The company did not provide updated guidance on share price targets or capital raising plans in this update.
Recce Pharmaceuticals' Use of Employee Options for Incentives
The multiple unquoted option classes—RCEAW, RCEAO, RCEAU, RCEAP, and RCEAQ warrants—reflect Recce Pharmaceuticals’ ongoing use of equity-based incentives as part of its remuneration and retention strategy. Such plans are common among ASX-listed biotech and pharmaceutical firms to align employee and shareholder interests, especially given the sector’s long development timelines and limited cash resources.
The lapse of these options indicates that some grant conditions were not met within the required timeframe, possibly due to personnel changes, corporate milestones, or performance targets. The company did not specify the unmet conditions in the update; investors seeking further information should consult the latest Annual Report or remuneration disclosures.
Investor Considerations Following Recce Pharmaceuticals' Securities Termination
While the termination of 130,001 unlisted options is a routine administrative matter for Recce Pharmaceuticals, investors should continue monitoring the company's unquoted securities register for further changes, new employee incentive grants, and the progress of remaining option classes toward vesting or exercise conditions.
Beyond capital structure, investors will likely focus on Recce Pharmaceuticals’ clinical and commercial advancements in its pharmaceutical pipeline, which underpin the value of employee incentives. This securities cessation notice did not appear to trigger an immediate share price reaction, reflecting its administrative nature rather than operational impact. Additional company updates are expected as Recce progresses its development programs and reports on its pipeline.
